Therefore, it is worthwhile to further deeply study the molecular mechanism and clinical application of IL-2 as a new adjuvant therapy for patients with FHL-4 and FHL-5 who have not yet found a suitable donor for hematopoietic stem cell transplantation. The gene discussed is IL2; the disease is hemophagocytic syndrome.